WuXi AppTec re­cruits new CMO; Em­bat­tled Alk­er­mes makes case for ex­pand­ed use of schiz­o­phre­nia drug Aris­ta­da

→ Chi­na’s WuXi AppTec has re­cruit­ed Fred­er­ick Hausheer as its chief med­ical of­fi­cer. That gives him a glob­al op­er­a­tional role with their clin­i­cal op­er­a­tions in the US, Chi­na and around the globe. The 30-year vet found­ed BioN­u­merik Phar­ma­ceu­ti­cals, worked at the NCI and has been on fac­ul­ty at Johns Hop­kins.

→ A trou­bled Alk­er­mes $ALKS is tout­ing new tri­al da­ta this morn­ing demon­strat­ing that its schiz­o­phre­nia drug Aris­ta­da giv­en once every 2 months was equal to In­ve­ga Susten­na on a once-month­ly dose in con­trol­ling symp­toms of the dis­ease. The 6-month study start­ed treat­ment af­ter an acute in­ci­dence fol­lowed by their tran­si­tion back to the com­mu­ni­ty. The biotech is hop­ing to ex­pand its rev­enue against the leader in the field. Alk­er­mes re­cent­ly was bat­ted back by the FDA af­ter try­ing to gain an ap­proval for their new de­pres­sion drug, which in­flict­ed se­vere dam­age on their stock price.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER